Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autoantigen mRNA-LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Experimental hematology & oncology·2026

Same author

Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.

Molecular therapy. Oncology·2025

Same author

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

Journal of hematology & oncology·2025

Same author

Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways.

Cell reports·2025

Same author

Immune modulation following α and β<sup>-</sup> radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.

Oncoimmunology·2025

Search research articles

Related Experiment Video

Updated: Apr 24, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

mRNA-based dendritic cell vaccines.

Daphné Benteyn¹, Carlo Heirman, Aude Bonehill

¹Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103/E, 1090 Jette, Belgium.

Expert Review of Vaccines

|September 9, 2014

Summary

Cancer immunotherapy uses mRNA-modified dendritic cells (DCs) to stimulate T cells for cancer treatment. These vaccines show promise in clinical trials for generating anti-cancer immune responses.

Keywords:

cancer cytotoxic T cell dendritic cell mRNA tumor antigen

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Related Experiment Videos

Last Updated: Apr 24, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Cancer immunotherapy aims to harness the patient's immune system to combat cancer.
T cells are crucial for recognizing and eliminating cancer cells, forming immunological memory.
Dendritic cells (DCs) are key antigen-presenting cells that can be programmed to elicit T cell responses.

Purpose of the Study:

To introduce cancer immunotherapy and the role of dendritic cells (DCs).
To provide an overview of using messenger RNA (mRNA) to engineer DCs for cancer vaccines.
To highlight the potential of mRNA-modified DC vaccines in cancer treatment.

Main Methods:

Reviewing the principles of cancer immunotherapy and T cell activation.
Explaining the function of dendritic cells in antigen presentation.
Detailing the application of mRNA technology for programming DCs.

Main Results:

mRNA is a safe and efficient molecule for programming DCs.
mRNA-modified DC vaccines have demonstrated promising results in clinical trials.
This approach can stimulate cancer-specific T cell responses.

Conclusions:

mRNA-modified dendritic cell vaccines represent a promising strategy in cancer immunotherapy.
The technology offers a well-defined and pure method for vaccine development.
Further clinical investigation of these vaccines is warranted.